Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of AK130 in Advanced Malignant Tumors
NCT05653284Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2023
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lucorafusp alfa in cancer, sponsored by Akeso, Inc. Primary endpoints: Incidence and severity of participants with adverse events (AEs) and Number of participants with Dose Limiting Toxicities. Started Feb 2023; status: completed.
02
Drugs
lucorafusp alfa
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05653284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653284.